Literature DB >> 3891388

Assignment of the structural gene for subunit M1 of human ribonucleotide reductase to the short arm of chromosome 11.

Y Engström, U Francke.   

Abstract

By using a species-specific monoclonal antibody that recognizes subunit M1 of ribonucleotide reductase from human but not hamster origin, we have been able to assign the structural gene for the human protein M1 to the short arm of chromosome 11. Protein extracts from a panel of human-Chinese hamster somatic cell hybrids were subjected to electrophoresis in sodium dodecyl sulfate (SDS) denaturating polyacrylamide gels, and then transferred and coupled covalently to diazobenzyloxymethyl paper. These were screened for human protein M1 by incubation with the mouse monoclonal anti-M1 antibody AD 203, followed by rabbit anti-mouse IgG, 125I-labelled Staphylococcus protein A and finally autoradiography. In all tested hybrids the detection of human protein M1 was correlated with the presence of chromosome 11, specifically with the short arm of this chromosome. This region also contains the human genes for insulin, insulin-like growth factor II, and the c-Harvey-ras 1 oncogene.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891388     DOI: 10.1016/0014-4827(85)90470-7

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

1.  A common SacI polymorphism in the gene for the M1 subunit of ribonucleotide reductase (RRM1).

Authors:  L Battat; U Francke
Journal:  Nucleic Acids Res       Date:  1989-05-25       Impact factor: 16.971

Review 2.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

3.  Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.

Authors:  S Wadler; H Haynes; R Schechner; A Rozenblit; P H Wiernik
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.